Top 5 Breakthrough Pharmaceutical Drugs of the Decade

  1. Carvykti

  2. Peak Sales Estimate at the Time of Approval (USD Billion): 5

    Disease: Multiple myeloma

    Company: Johnson & Johnson, Legend Biotech

    Carvykti, a CAR T-cell therapy for multiple myeloma, saw flat sales between Q3 and Q4 2022, generating $55 million each quarter. J&J says sales align with expectations, and it is expanding the network of centers offering the therapy in a phased approach. Despite being a valuable option for hard-to-treat cancers, CAR-T treatments have faced commercial obstacles.